Hello, and welcome back to the Bell Potter Healthcare Conference. For our next session, we are very pleased to be joined by the CEO of Immutep, Marc Voigt. Marc, welcome. Thanks for joining us. How are you going today?
Thank you so much, Thomas. I'm going okay. Thank you.
Very good. I'm going to do a quick introduction here, and then we'll pass it to you for some slides. It's fair to say that 2026 was one of the tougher years for Immutep. Following the unexpected result of a futility analysis, the company was required to discontinue a phase III trial in lung cancer. However, while that was a difficult outcome for those involved, it wasn't the only game in town. After an initial root cause analysis, there continues to be a path forward for efti in other oncology indications where earlier data is encouraging. Additionally, Immutep has been developing a second asset, which is now progressing through early clinical trials targeting patients with autoimmune disorders. So, there is plenty to keep our interest and the investor community engaged over the next near term.
With that, Marc, please take us through your slide presentation, and we'll follow up with some Q&A afterwards.
Yeah. Thank you so much, Thomas. Much appreciated. Thank you for providing us with the opportunity to present here. Here is my presentation, a forward-looking statement. First of all, indeed, it has been a very tough year for Immutep. The phase III discontinuation is not easy. However, as you said, we have our main fundament intact. We are active in immuno-oncology as well as in autoimmune diseases. We are focused on LAG-3, one of the validated immune checkpoints, meaning we have an FDA-based product upon them. Beyond PD-1, CTLA-4, LAG-3 is certainly promising in terms of its potential for future treatments in oncology as well as in autoimmune diseases. We have a diversified portfolio. We have also different partners. That is a core piece of our strategy, to work with partners from the industry, also from the academia.
We are well-financed with close to AUD 50 million cash on bank end of last quarter. Our pipeline looks quite diversified. We have a number of different clinical trials. We conducted with eftilagimod a number of clinical trials successfully. Unfortunately, we had to discontinue the phase III clinical trial based on a futility analysis earlier this year. However, we have been performing a root cause analysis and press released in September that we do see some differences in terms of the product as such, so efti, at 2,000 L scale. We will be clearer at our upcoming AGM, 27th of November, where the root cause analysis stands and what we can derive from that for the future development of eftilagimod.
Importantly, we have contracted a new 200 L run, so those which have been working well in different clinical trials with efti, and where we can focus to move forward in different indications such as head and neck cancer, CPS below one, and soft tissue sarcoma. We have other assets, and one very important asset has been delivering quite nicely. It is called IMP761, and it is the world's first agonist to LAG-3 positioned in autoimmune diseases. There we have been generating very promising results. I will show some of that later on. We have now, with the results from 761 as well as efti, two core priorities, meaning efti is no longer the only flagship, but we have two assets which we will advance clinically and which have been delivering in different ways.
Most recently, both of them delivered data, eftilagimod, for instance, in soft tissue sarcoma, and IMP761 in a phase I clinical trial, a sizable phase I should say, with up to 80 healthy volunteers and a very interesting setting. Let us look at oncology first. In oncology, we have on the one hand side the opportunity to move forward in head and neck cancer, CPS below one, which is, I believe, the most underserved patient population in head and neck cancer. Those patients have a relatively short life expectancy. Unfortunately, KEYTRUDA as a monotherapy is not approved in that segment, and every single treatment there has a chemo backbone. All patients are exposed to chemotherapy in combination with different other therapies, and we would like to offer those patients a chemo-free solution.
We discussed that with the FDA last year, and we are focused on moving forward in a registration-directed setting, which, subject to all the available allowances, partnering, and resources, we would like to start second half of next year. The data we have been delivering there, I believe, is very good, and final overall survival data from this indication will come up by mid of December at ESMO IO, and we have also fast track designation from the U.S. FDA. Another indication is resectable soft tissue sarcoma, where we test eftilagimod in combination with radiotherapy and anti-PD-1 in the so-called neoadjuvant setting. Meaning prior to surgery, you deliver eftilagimod in order to bring the immune system up to speed and have a better outcome for the patients, measured, for instance, in disease-free survival.
Unlike in head and neck cancer or lung cancer or breast cancer, where we have been delivering clinical results in the past, here we look at the primary tumor, treat the primary tumor, bring the immune system up to speed, and this should translate into better disease-free survival as the tumor is removed by surgery. The results we have seen to date are very promising. Primary endpoint of this study has been reached with a very good P-value. It is an investigator-initiated trial. In April of this year, we have been receiving orphan drug designation in this indication. This was after the phase III discontinuation, and the FDA was kind enough to give us orphan drug here. Going over to autoimmune diseases. In autoimmune diseases, we have two assets, IMP731 and IMP761.
Here, I will talk about IMP761, which is a first-in-class LAG-3 agonist antibody, which is designed to focus, if you like, on the rogue T-cells, which are relevant in up to 80% of autoimmune disease settings. Those rogue T-cells are characterized by expressing LAG-3. Here you see the basic concept. The T-cell is constantly exposed to the self-peptide at disease site, is expressing LAG-3, and we are using this antibody, which took a decade to create, to specifically silencing those cells, not destroying the immune system, which you sometimes see in other approaches. We are focusing on the specific cells which are relevant to drive so many different autoimmune diseases. This could be relevant, for instance, in rheumatoid arthritis, it could be relevant in type one diabetes, and in also very tough indications like multiple sclerosis. These are also very attractive markets.
If you make in autoimmune diseases, same applies for oncology, a difference to unmet medical need, then this will translate also, of course, into commercial benefit later on. We are focusing on the root cause, while many different other approaches in autoimmune diseases and approved drugs are more focused on the downstream signals and downstream molecules. We are going after the root cause of the disease. It is a very differentiated approach, which will be tested hopefully in a phase II clinical trial in second half of next year. The results we have been showing most recently, beginning of November at the American College of Rheumatology Convergence, have been highly encouraging. First of all, one could say, "Hey, look, it is a phase I, which is predominantly looking at safety, of course. Why is this exciting?" This phase I is a very different animal.
We have been exposing IMP761 to a very hard test at the beginning. We look at the double-blind, randomized, placebo-controlled phase I clinical trial. Healthy volunteers come to the clinic, and they get their skin locally, deliberately irritated. You cause, if you like, a local inflammation, and then you give either, in a blinded fashion, placebo to the one healthy volunteer and IMP761 to another one, so that you can compare and eliminate the placebo effect, which in autoimmune diseases can be up to 30% or 40%, depends on the indication. We have been showing the effects with IMP761 in terms of blood perfusion and in terms of T-cell reduction. These are markers for inflammation and autoimmune disease, very relevant, are statistically significantly different between those groups.
If you look at the dose exposure and where the subject had a low exposure compared to high exposure, the difference in terms of these parameter is statistically significantly different in favor of IMP761. In a very hard test, which is also used by the industry, we have been delivering, I believe, quite nicely with IMP761. Moving forward, it's very important to be disciplined. On the one hand side, we are working on de-risking eftilagimod. On the one hand side, the root cause analysis. Again, I would like to point to the AGM, 27th of November. We contracted 200-L manufacturing scale, and then efti advancement in terms of head and neck cancer, CPS below one, and also soft tissue sarcoma, the neoadjuvant setting, so that we can move forward in those settings second half of next year. That would be ideal.
We have partners we discuss with. On the one hand side, we are very thankful for the support from Dr. Reddy's, and on the other hand side, of course, we discuss with existing and potential new partners for eftilagimod. IMP761, everything we delivered so far, I believe, is quite promising. There we are working on advancing this program. We have a number of discussions also with potential partners around IMP761, and we will be very disciplined to move forward with these different assets and have a rational decision-making around the concepts. To sum up, on the one hand side, we have, I believe, a portfolio of different assets, and these assets have exciting paths forward. This applies on the one hand side to eftilagimod, on the other hand side to IMP761.
Both are under rigorous planning, and of course, we are making a gated decision-making, meaning every decision we take to advance in this or that indication is checked and needs to fit to our resources, needs to fit to the partnering needs in order to create value to our shareholders. This is, of course, a key point, especially as you have been experiencing the phase III discontinuation, which is a prerequisite to learn from that, take these learnings, apply them into your development progress, and move forward with the right plan, the right team, the right financial resources. We have close to AUD 50 million, and I believe we are well-positioned to rebuild the share price, rebuild the value of this company. This is exactly the mission we need to focus on, and we will do that.
On the other hand side, if you look at the company, if you look at our market cap, if you look at our available assets and resources, including the cash, I believe it has also an interesting perspective for potential new investments. Thank you so much. That's the presentation, and I'm open for Q&A.
Fantastic. Thanks, Marc Voigt, for the run-through. We've got a few minutes here, so we'll get through some Q&A. I want to start on head and neck cancer. You mentioned that there's, I think, a final data or an additional data presentation coming up in the not-too-distant future, so that's really exciting. Maybe at a high level, what will those additional data points entail compared to maybe some of the previous data points or follow-up periods reported previously?
Important question, Thomas. Thank you. First of all, that presentation will be mid of December, I believe 16th, 17th, 18th, if I'm not mistaken, at the ESMO IO. While we have been presenting, I believe, very good data in the past in terms of response rates, 35% in terms of the safety side of things, also in terms of mature overall survival, we can now expect final overall survival. Are the results we have been showing earlier on in line with the new and final overall survival data is the key question, and final overall survival is, of course, always a very important inflection point.
Great. That patient population, CPS less than one, so that's basically patients who don't respond to immune therapy typically. Why the focus on that subgroup? It seems like there's clearly a huge unmet need there. Is that the key reason?
Yes, that is absolutely correct. Plus a few additional important points here. On the one hand side, you have only very limited competition here, and to focus on a specific segment which is well-defined by a biomarker, where you have seen previously exciting results, and where you have relatively low competition, which would enable you to recruit relatively swiftly, and which makes also the competent authority more amenable, let us say, to look at accelerated approval. These are key considerations to move forward there. If you focus on, let us say, the whole patient population, head and neck cancer, this would mean you would need to go from start with a randomized study, very large, would compete for the patients. We go after the data, after the regulatory prerequisites and the regulatory sweet spots we are having there with fast track designation, and where we face limited competition.
Great. Yeah, that makes sense. With that fast track designation, I imagine you are engaging with the regulators to try and hone in on what that next clinical trial may be in order to get you through to that approval potentially.
Yes, and the good thing is we did that already mid of last year. We have been discussing with the FDA. Of course, we will have additional regulatory interactions coming up in the next year. But we already discussed the data, we discussed the path forward, and we could, for instance, go into a single-arm clinical trial, phase II single-arm clinical trial, and aim for accelerated approval. Of course, to support that approval, you would need to start a phase III clinical trial, but you would already know the phase II data by and large before you start such a clinical trial.
Yeah, interesting. That is certainly a path that in other similar kind of oncology indications has been the case. We just got a minute or two left, so I want to quickly shift to IMP761. You put out the poster presentation and the data you highlighted just earlier showing T-cell reductions in these volunteers when they were challenged. Give us a sense of what some of the specific indications are where the overactivation of T-cells leads to the symptoms and the disease, and where IMP761 could potentially have a path in the clinic.
Yeah. That's the beauty and the challenge of that program. The beauty and challenge is that you could apply this product to a number of different autoimmune diseases. Depends on how you count, you have between 100- 200 different autoimmune diseases, and IMP761 could be active in up to 80. However, we do have already some data, and the data you saw on the poster is, for instance, in rheumatoid arthritis, and we have also some data in juvenile arthritis. Rheumatoid arthritis could be a natural entry point where, at the end of the day, you measure pain of patients experiencing, let's say, a medium to severe rheumatoid arthritis, and of course, to lower that pain and to make the joints better movable, this could be a key goal for IMP761 and could be an entry point.
Another one would be type one diabetes, and there could also be a number of different dermatology indications, psoriasis, atopic dermatitis. We actually work with a third party on ranking all the different indications we could potentially apply and come up with a good plan that also, in terms of the dosing, we are going to discuss all these aspects with regulators also in the coming period of time, meaning in 2027. There is a lot to do, but I believe we have some good ideas how to advance this in a meaningful phase II clinical trial.
Yeah, absolutely. Those indications you mentioned are massive blockbuster opportunities across different autoimmune conditions where we see some biologics already generating a lot of returns in terms of sales and also clinical benefit. Marc-
[inaudible], HUMIRA, sorry to interrupt you there, Thomas.
Yeah, please.
That is absolutely right. These are multi-billion dollar markets, and prior to KEYTRUDA and oncology, HUMIRA has been the number one drug in the world in terms of annual sales. These markets are absolutely massive, and if you are delivering benefit to the patients, this will pay off later on.
Yeah, absolutely. AbbVie are doubling down in those indications as well, so it is not going away anytime soon. Marc, I know we are out of time, so I just want to thank you. I guess looking forward in the near term, we have your AGM at the end of November. You mentioned there should be an update on FDA. Mid to late December, we have the update in head and neck cancer, and it sounds like some additional clinical and regulatory updates on efti in soft tissue sarcoma as well. So, it has obviously been a difficult year, but there is some positive and exciting news flow events clearly to come in the near term. We will be definitely looking out with interest at those.
Thank you so much, Thomas. We are determined to fight, and I believe we have good reasons to do so, and I believe good plans which we will advance. Thank you so much.
No worries. Drug development is rarely a straight line, so it is a long game, and well done with your perseverance. We continue to look forward to those updates. All right.
Thank you so much.
Thank you, everyone, for listening. We are going to go to a quick break, and we will be back shortly with our next presentation. Thank you.